Home MarketDr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. Stock Info: As on 2018-05-24 15:47:39

Nse

890.05

7.55(0.86%)
Change%
52 Week Range
723.05
24.00
932.50
15.00
Open875.00
Day's Range706.00 - 1,059.00
Value Traded (in ₹ Cr.) 8.79

Bse

890.80

7.45(0.84%)
Change %
52 Week Range
717.65
24.00
930.60
15.00
Open874.55
Day's Range706.68 - 1,060.02
Value Traded (in ₹ Cr.) 0.12

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 47,848,562.00 57.42%
Mutual Funds/UTI 8,425,504.00 10.11%
FII 11,068,271.00 13.28%
Employee 0.00 0.00%
Public 4,193,690.00 5.03%
Government 0.00 0.00%
Others 9,434,297.00 11.32%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 9.11
Basic EPS (Rs.) 17.77
Cash EPS 21.57
BVPerShare Excl 75.24
Operating Revenue 106.17
PBDITPerShare 28.47
Dividend 3.00
NPPerShare 17.72
Current Ratio 6.98
Quick Ratio 6.74
PriceToBV 12.86
Earnings 0.01
PBDIT Margin 26.81
PBT Margin 25.27
NP Margin 16.69
Return On Assets 20.32
Retention Ratios 92.66
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 889.24
Total Expenses 666.34
EBITDA 236.46
PBT 222.90
PAT 147.21
Net Income 147.21
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 528.60
Total Expenses 413.10
EBITDA 98.10
PBT 115.10
PAT 74.70
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 83.07
Net worth 624.97
Investments 132.96
Total Liability 724.12
Total debt 0.00
Net block 150.08
Total Assets 724.12
Parameter Mar-17 (₹ Cr.) 6M % change
Total share capital 81.26
Net worth 319.24
Investments 49.36
Total Liability 449.18
Total debt 0.00
Net block 119.97
Total Assets 449.18
Company Curr Price Prev. Close Change% W's Low/High

Apollo Hospitals Enterprise Ltd.

966.55 963.95 0.27
9571038

Aster DM Healthcare Ltd.

179.6 177 1.47
175.95190.6

Fortis Healthcare Ltd.

142.95 144.9 -1.35
143.25152.9

Healthcare Global Enterprises Ltd.

304.25 302.8 0.48
300314

Indraprastha Medical Corporation Ltd.

45.75 45.4 0.77
4547.75

Kovai Medical Center and Hospital Ltd.

641.65 624.85 2.68
629.9649.9

Lotus Eye Hospital and Institute Ltd.

29.85 29.75 0.34
27.6530.95
Company Curr Price Prev. Close Change% W's Low/High

ADS Diagnostic Ltd.

11.34 10.8 0
11.3411.34

Apollo Hospitals Enterprise Ltd.

969.75 966.3 0.36
956.851035.7

Aspira Pathlab & Diagnostics Ltd.

17.82 16.98 4.95
17.8217.82

Aster DM Healthcare Ltd.

0 0 0
176.25190.75

Birla Pacific Medspa Ltd.

0.28 0.27 0
0.270.28

CDR Health Care Ltd.

7.58 2.6 0
7.227.58

Chennai Meenakshi Multispeciality Hospital Ltd.

21.8 21.8 0
21.823.8
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 167.00
Cash from investing activities -137.65
Cash from financing activities -33.78
Net change in cash -4.43

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Franklin India Prima Plus 1.07%
Franklin India Smaller Companies Fund 1.66%
UTI Equity Fund 1.34%
UTI Bluechip Flexicap Fund 1.35%
UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan 0.56%
UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan 0.56%

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

24-May-2018 09:29 AM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBl (Listing Obligations and Disclosure Requirements)
Regulations, 2015, the details of proposed schedule of Analyst/lnstitutionaI lnvestor meetings is as per the attachment.

24-May-2018 09:24 AM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the details of proposed schedule of Analyst/Institutional Investor meetings are as per the attachment

16-May-2018 03:00 PM

Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

16-May-2018 02:56 PM

Dr. Lal Pathlabs Ltd - AGM/Book Closure

Dr. Lal Path Labs Ltd. has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from August 7, 2018 to August 13, 2018 (both days inclusive) for the purpose of Payment of dividend and Annual General Meeting of the Company is scheduled to be held on August 13, 2018.

15-May-2018 07:16 PM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBl (Listing Obligations and Disclosure Requirements)
Regulations, 2015, the details of proposed schedule of Analyst/lnstitutionaI lnvestor meetings is as per the attachment.

24-May-2018 09:24 AM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the details of proposed schedule of Analyst/Institutional Investor meetings are as per the attachment

16-May-2018 03:00 PM

Dr. Lal Pathlabs Ltd - Fixes Book Closure for Dividend & AGM (Cut-off date for e-voting)

Dr. Lal PathLabs Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 07, 2018 to August 13, 2018 (both days inclusive) for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on August 13, 2018.

15-May-2018 10:32 AM

Corporate Details

About Management

Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company.

Registered Office

12th Floor, Tower B, SAS Tower, Sector 38, Medicity,

0124-3016500,,,      0124-4234468,

cs@lalpathlabs.com

https://www.lalpathlabs.com

Registrar Details

Link Intime India Pvt. Ltd.